The pharmacokinetic profile of Actrapid InnoLet has been studied in a small number (n=18) of diabetic children (aged 6-12 years) and adolescents (aged 13-17 years).
Iphrofayili ye-pharmacokinetic ye-Actrapid NM yafundwa eqenjini elincane lezingane ezinesifo sikashukela i-mellitus (abantu abangu-18) abaneminyaka engu-6 kuya kwengu-6, kanye nentsha (eneminyaka eyi-13 kuya kwengu-13).